Directors at Ironwood Pharmaceuticals Inc. have green-lit plans to spin off the company's R&D programs into a new publicly traded company, a move that could help sales of Linzess (linaclotide) and other approved treatments carry the commercial business to profitability in 2019 while compartmentalizing risks of its rare disease-focused soluble guanylate cyclase (sGC) stimulator programs.